Ceapro (CRPOF) Stock Price, News & Analysis

Company Overview

Ceapro Inc. is a Canadian biotechnology company focused on developing and commercializing products derived from natural plant sources. The company’s work has centered on the extraction, purification and formulation of bioactive compounds from oats and other botanical materials for use in pharmaceutical, nutraceutical, cosmetic and personal-care applications.

Ceapro’s product portfolio has included oat beta-glucan, avenanthramides and related oat-derived ingredients. These compounds are used in products positioned for skin care, inflammation management, immune support and general health. The company has also pursued proprietary extraction and formulation technologies intended to improve the consistency, functionality and commercial applications of plant-based ingredients.

Founded in 1997 and based in Edmonton, Alberta, Ceapro has served customers and development partners in international markets through the sale and licensing of its ingredients and technologies. The company has historically been led by Gilles Gagnon, who served as president and chief executive officer. Its operations have included research and development, product manufacturing and collaboration with pharmaceutical, cosmetic and consumer-health companies.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.11 to $0.40
• Volume: N/A
• Average Volume: 15,466 shs
• Market Capitalization: $13.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CRPOF
• CIK: N/A
• Web: www.ceapro.com
• Phone: (780) 421-4555
• Fax: 780-421-1320
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.49 million
• Net Margins: -69.60%
• Pretax Margin: -31.44%
• Return on Equity: -20.30%
• Return on Assets: -18.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.00
• Quick Ratio: 7.72

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 1.86
• Cash Flow: $0.06 per share
• Price / Cash Flow: 2.74
• Book Value: $0.32 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 78,293,000
• Free Float: N/A
• Market Cap: $13.31 million
• Optionable: Not Optionable
• Beta: 1.47